Latest news with #Flyrcado
Yahoo
15 hours ago
- Business
- Yahoo
GE HealthCare's Flyrcado Sets New Benchmark in Cardiac PET Imaging
GE HealthCare GEHC recently unveiled new advancements in precision cardiac care at the 2025 SNMMI annual meeting in New Orleans, with a spotlight on Flyrcado—its FDA-approved Positron Emission Tomography (PET) imaging agent for myocardial perfusion imaging (MPI). As cardiovascular disease continues to rise globally, GEHC emphasized Flyrcado's role in enabling more accurate diagnosis, treatment planning, and broader access to personalized cardiac care through advanced molecular imaging. Flyrcado reflects GEHC's broader focus on advancing precision cardiac care through molecular imaging. It plays a key role in enabling earlier disease detection, personalizing treatment strategies, and monitoring therapy response or disease progression. The company highlighted Flyrcado at the 2025 SNMMI annual meeting, reinforcing its commitment to delivering advanced diagnostic tools that improve outcomes for the growing population at risk of cardiovascular disease. GEHC's Flyrcado (flurpiridaz F 18) is a fluorine-18 PET MPI agent developed for patients with known or suspected coronary artery disease. Flyrcado has a longer half-life of approximately 110 minutes. This allows for centralized production and broad distribution. For the first time, it also enables the practical integration of exercise stress testing with cardiac PET imaging. Compatible with GEHC's Omni Legend PET/CT and other systems, the agent is designed to support detailed assessment of myocardial perfusion, ischemia, and infiltrative cardiomyopathies. Recently launched in select U.S. markets, Flyrcado received CMS pass-through status effective April 1 and is supported by a specific HCPCS billing code. The agent is now covered by all seven Medicare Administrative Contractors and by more than 50% of commercial insurers under updated national and regional cardiac PET policies. Coverage has expanded beyond hospital outpatient settings, and GEHC has established a dedicated Flyrcado Support Center to assist providers with coding, benefits investigations, and claims submissions. Shares of the company closed flat at $71.16 yesterday following the announcement. In the year-to-date period, GEHC shares have lost 9% against the industry's 4% growth. The S&P 500 increased 0.8% in the same time frame. Flyrcado positions GEHC for long-term growth by expanding its presence in the high-value molecular imaging market, where demand for precision cardiac diagnostics is rising. With broad payer coverage, CMS reimbursement, and compatibility with existing PET/CT systems, Flyrcado can accelerate the shift from SPECT to PET imaging—unlocking recurring revenue from both radiopharmaceutical sales and imaging hardware. As adoption scales beyond hospitals in outpatient settings, Flyrcado strengthens GEHC's precision care portfolio and supports its strategy to drive margin expansion through innovation-led, high-utility diagnostics. Meanwhile, GEHC currently has a market capitalization of $32.64 billion and carries a Zacks Rank #4 (Sell). In the last reported quarter, GEHC delivered an earnings surprise of 10.9%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Image Source: Zacks Investment Research Koninklijke Philips PHG has recently accelerated its cardiac imaging leadership through advanced AI integration in both CT and ultrasound modalities. In January 2025, the company launched the AI-enabled CT 5300, a 128-slice CT system equipped with AI-powered cardiac motion correction and reconstruction at AOCR 2025, enhancing image clarity, speeding workflows, and reducing radiation exposure in cardiac scans. Complementing this, Philips' Spectral CT 7500 continues to deliver 'always-on' dual-layer spectral imaging, FDA-cleared for 4D respiratory-gated applications, offering clinicians the ability to assess coronary arteries and myocardial perfusion with superior diagnostic confidence during a single, swift scan. Nano-X Imaging Ltd. NNOX through its AI imaging division received FDA 510(k) clearance for HealthCCSng V2.0 in August 2024, an AI-powered solution that automatically quantifies coronary artery calcium (CAC) from routine non-gated chest CT scans, adding a 'zero calcium' category and numerical scoring for more nuanced risk stratification. At SCCT 2024, real-world studies were showcased, including evidence from Brigham & Women's Hospital demonstrating that HealthCCSng flagged incidental CAC in more than 50% of immune-mediated inflammatory disease patients highlighting its potential for early detection and preventive care across broad clinical settings. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report Nano-X Imaging Ltd. (NNOX) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Wire
2 days ago
- Health
- Business Wire
GE HealthCare enhances cardiac diagnostics with innovative molecular imaging solutions showcased at SNMMI 2025
CHICAGO--(BUSINESS WIRE)--GE HealthCare's commitment to advancing precision care in cardiology through innovative molecular imaging solutions is on full display at this week's Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana. 'Flyrcado represents one of the most significant advancements in nuclear cardiology in decades,' shares Marcelo Fernando DiCarli, MD, Chief, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Executive Director, Cardiovascular Share As cardiovascular disease (CVD) continues to rise globally, i the need for advanced diagnostic technologies becomes increasingly critical. GE HealthCare's molecular imaging technologies – including positron emission tomography-computed tomography (PET/CT) and single-photon emission computed tomography-computed tomography (SPECT/CT) – and radiopharmaceuticals – namely its Flyrcado™ (flurpiridaz F 18) injection – play a crucial role in cardiac care by providing detailed insights into biological processes beyond conventional imaging. These advanced imaging techniques enable early diagnosis, precise assessment of myocardial perfusion and ischemia, and evaluation of infiltrative cardiomyopathies. By identifying specific pathologic processes, molecular imaging helps tailor treatments to individual patients, with the aim to enhance the effectiveness of therapies and improving prognosis. Additionally, it allows for monitoring treatment responses and disease progression, ultimately helping contribute to better patient outcomes. ii 'Flyrcado represents one of the most significant advancements in nuclear cardiology in decades,' shares Marcelo Fernando DiCarli, MD, Chief, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Executive Director, Cardiovascular Imaging Program, Departments of Radiology and Medicine, Brigham and Women's Hospital. 'For the first time in nearly 20 years, we have a new PET myocardial perfusion tracer that brings the latest imaging technology within reach for patients across the U.S. The image quality is exceptional, and its use has the potential to reduce unnecessary invasive procedures by improving diagnostic confidence. I've found it to be a valuable addition to our clinical practice, enabling more personalized treatment strategies and better patient outcomes. The excitement across the cardiology community is evident as we enter a new era in precision cardiac care.' GE HealthCare's Flyrcado injection, a first-of-its-kind F 18-unit dose PET myocardial perfusion imaging (MPI) agent for patients with known or suspected coronary artery disease (CAD), helps clinicians deliver higher diagnostic efficacy compared to SPECT MPI, the predominant procedure used in nuclear cardiology today. Recently launched in select U.S. markets, Flyrcado's availability aligns with its receipt of CMS pass-through status, effective April 1, which includes a drug-specific HCPCS billing code to support efficient coding and Medicare coverage. In addition, Flyrcado is now covered by all seven Medicare Administrative Contractors (MACs) at either invoice price or better, depending on the site of care. More than 50% of commercially insured beneficiaries are now covered under updated national and regional cardiac PET policies that include Flyrcado as a covered benefit—marking significant progress in expanding access beyond the hospital outpatient setting. Further expansion is expected in the second half of the year as additional payors complete their policy reviews. To support this evolving access landscape, GE HealthCare has launched the Flyrcado Support Center (800-729-0701) to assist customers with benefits investigations, coding, coverage, and claims submissions. 'With coverage now in place for all traditional Medicare beneficiaries, along with updated PET coverage policies in place for more than half of the nation's commercially insured beneficiaries, millions of Americans—many at risk for or living with coronary artery disease, the leading cause of death in the U.S.—will have greater access to this innovative technology,' said Eric Ruedinger, Vice President and General Manager of GE HealthCare's Pharmaceutical Diagnostics division for the U.S. and Canada. 'Flyrcado represents a significant advancement in cardiac care over SPECT imaging, offering clinicians a new, highly effective diagnostic tool to support more timely and personalized care for patients with known or suspected coronary artery disease.' Flyrcado can be imaged with a range of PET/CT systems, including GE HealthCare's Omni Legend, offering clinicians flexibility in integrating this innovative tracer into their existing imaging workflows. With Flyrcado, clinicians have the first practical opportunity to combine exercise stress testing with cardiac PET imaging for CAD, providing a highly effective protocol for evaluating ischemia in patients. Beyond Flyrcado, Omni Legend enables exceptional cardiac diagnostics, accommodating a range of tracers – including fast decay and emerging tracers. Representing a scalable PET/CT platform designed to evolve with healthcare system needs across care areas with shorter scan times and lower doses, iii it continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. iv GE HealthCare is also proud to provide its StarGuide and Aurora SPECT/CT systems, designed to capture gamma rays emitted by radioactive tracers. Both systems offer exceptional image quality and scan time efficiency, supporting clinicians in making confident diagnoses. These features make SPECT/CT a valuable tool in cardiac care, providing comprehensive views of both physiological and structural aspects of diseases. Additional solutions from GE HealthCare's MIM Software are also available to enable multi-modality viewing and fusion of cardiac images and offer integration pathways for cardiac analysis. A devoted provider of cardiology solutions, GE HealthCare supports the continuum of care and personalized treatments for the world's largest hospitals to the smallest clinics and beyond the walls of the clinician's office. With a vast and diversified portfolio, GE HealthCare offers healthcare professionals a breadth of solutions from early detection and diagnosis, to planning, intervention, and monitoring to help clinicians deliver better patient outcomes in cardiology care today and for the future. For more information on GE HealthCare's innovative portfolio of molecular solutions for cardiology, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. Forward-looking statements This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as 'will,' 'expect,' 'may,' 'would,' 'could,' 'plan,' 'believe,' 'anticipate,' 'intend,' 'potential,' and similar expressions. These forward-looking statements may include, but are not limited to, statements about Flyrcado and GE HealthCare Technologies Inc.'s (the 'Company's') performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company's actual results to differ materially from those described in its forward-looking statements include, but are not limited to, uncertainties regarding the commercial success of Flyrcado, the Company's ability to receive pass-through status from the US Centers for Medicaid and Medicare, and decisions by regulatory authorities impacting labeling, manufacturing processes, safety, or other matters that could affect the availability or commercial potential of Flyrcado. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company's actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation. Important Safety Information and Usage of Flyrcado™ (flurpiridaz F 18) injection FLYRCADO™ (flurpiridaz F 18) injection, for intravenous use important safety information Indications and usage FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. Contraindications None Warnings and precautions Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent's prescribing information. Radiation risks: FLYRCADO contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void. Adverse reactions Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia. Use in specific populations Pregnancy There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure. FLYRCADO contains ethanol (a maximum daily dose of 337 mg anhydrous ethanol). If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes associated with ethanol exposure during pregnancy. Lactation Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO administration. Pediatric Use Safety and effectiveness of FLYRCADO in pediatric patients have not been established.
Yahoo
31-03-2025
- Health
- Yahoo
GE HealthCare's Latest Product Launch to Boost Cardiology Care
GE HealthCare Technologies Inc. GEHC recently announced the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the ongoing American College of Cardiology (ACC) Annual Scientific Session & Expo. It also plans to unveil the latest version of CASE (Cardiac Assessment System for Stress Testing), powered by its CardioSoft technology, at the ACC. GE HealthCare also plans to showcase CardIQ Suite (an integrated workflow for the seamless review of calcium scoring and cardiac computed tomography angiography data) and its recently launched AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab editions. GEHC aims to highlight its strategy to leverage AI to help increase efficiency and enable seamless integration of data across the cardiology care pathway by showcasing its latest AI-powered innovations. The latest launch is expected to significantly strengthen GE HealthCare's Cardiology Solutions unit, thus boosting its overall business. Per GE HealthCare's estimates, around six million myocardial perfusion imaging (MPI) procedures are undertaken each year in the United States to show blood flow through the heart muscle and evaluate the presence, extent and degree of myocardial ischemia or infarction. Positron emission tomography (PET) is currently the most effective form of MPI for detecting coronary artery disease (CAD) and is recommended for a wide range of patients, including those considered more challenging to diagnose, over single-photon emission computed tomography (SPECT) MPI. GEHC further stated that the FDA approved Flyrcado for patients with known or suspected CAD in 2024. This is expected to deliver higher diagnostic efficacy, unlike SPECT MPI, the predominant procedure used in nuclear cardiology at present. GE HealthCare's management believes that the launch of Flyrcado represents a significant advancement in cardiac care, providing a new, highly effective diagnostic tool for those with known or suspected CAD. Additionally, Flyrcado has been granted traditional pass-through payment status by the U.S. Centers for Medicare and Medicaid (CMS). The receipt of pass-through status from the CMS, effective April 1, secures a drug-specific Healthcare Common Procedure Coding System or HCPCS billing code and coverage for traditional Medicare beneficiaries. Pass-through payment status will likely enable CMS to provide separate payments for radiopharmaceutical and PET-CT scan, when performed with Flyrcado in the hospital outpatient setting. Per a report by Grand View Research, the global coronary heart disease diagnostic imaging device market was estimated to be $2 billion in 2024 and is anticipated to witness a CAGR of 6.6% between 2025 and 2030. Factors like the increasing prevalence of CAD and the rising adoption of early diagnostic techniques are likely to drive the market. Given the market potential, the latest product availability is expected to provide a significant boost to GE HealthCare's business. This month, GEHC announced the launch of the AltiX AI.i edition of Mac-Lab, CardioLab and ComboLab. The AltiX AI.i edition is expected to enhance efficiency and precision care for multiple types of cardiac procedures. GEHC's peer in the cardiovascular space, Merit Medical Systems, Inc. MMSI, announced the enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in premature infants (PREEMIE study) this month. Per Merit Medical, the Bloom Micro Occluder System was designed as a minimally invasive option for treating hemodynamically significant PDA. The PREEMIE study has been developed to evaluate its safety and efficacy. Last month, Merit Medical reported its fourth-quarter 2024 results, wherein its Cardiovascular unit and all its product categories reported robust revenue growth. Another player and GE HealthCare's peer in the cardiovascular space is Medtronic plc MDT. This month, Medtronic released the two-year positive results of the Small Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international head-to-head comparative trial of transfemoral transcatheter aortic valve replacement. Last month, Medtronic reported its third-quarter fiscal 2025 results, wherein its Cardiovascular Portfolio witnessed a robust revenue uptick on both reported and organic basis. Another renowned peer in the cardiovascular space is Abbott Laboratories ABT. This month, ABT announced the receipt of the CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation. Following this, Abbott has begun commercial PFA cases in the European Union (EU) with physicians who are familiar with the Volt PFA System within its PFA clinical studies. ABT plans to further expand the use of Volt in EU markets throughout the second half of the year. Abbott also announced this month that the FDA has approved an investigational device exemption for its Coronary Intravascular Lithotripsy System to evaluate the treatment of severe calcification in coronary arteries prior to stenting. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
31-03-2025
- Business
- Yahoo
GE HealthCare (GEHC) Debuts AI-Powered Cardiology Suite at ACC 2025!
We recently published a list of . In this article, we are going to take a look at where GE HealthCare Technologies Inc. (NASDAQ:GEHC) stands against other top AI ratings and news updates on Wall Street's radar. Despite AI's potential to transform our lives for the better, security threats associated with the technology continue to make headlines. North Korea's Kim Jong Un oversaw tests of newly developed AI-powered suicide drones and called for increased production. Kim Jong Un had reportedly said that unmanned control and AI capability should be prioritized in modern arms development. Elsewhere, Alabama Governor Kay Ivey banned Chinese AI tools over data security concerns. 'When it comes to the threat posed by the Chinese government, Alabama takes no chances. Our citizens' information must be protected in the strongest possible ways, which is why we are not only putting a ban on these two Chinese AI companies within our state government but also safeguarding our state's IT infrastructure from any foreign country of concern,' she said. Bill Gates also recently reiterated concerns about AI replacing most jobs. He believes the rate of advancements in AI could mean that the technology could replace many professions, including doctors and teachers. 'It's very profound and even a little bit scary — because it's happening very quickly, and there is no upper bound,' Gates said in a recent interview. However, he noted that certain types of jobs will likely never be replaced by AI. He said last year that he remains optimistic about the overall benefits of AI, like 'breakthrough treatments for deadly diseases, innovative solutions for climate change, and high-quality education for everyone.' We selected AI stocks by reviewing news articles, stock analysis, and press releases. We listed the stocks in ascending order of the number of hedge funds that hold stakes in them, as of Q4 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A radiologist in a lab examining a computed tomography scan of a patient. GE HealthCare Technologies Inc. (NASDAQ:GEHC) is a provider of healthcare solutions, new-age medical technology, cloud-first AI-enabled solutions, and data analytics services worldwide. On March 27th, GE HealthCare Technologies Inc. (NASDAQ:GEHC) announced the launch of the FDA-approved Flyrcado imaging agent for the detection of suspected coronary artery disease at the 2025 American College of Cardiology Annual Scientific Session & Expo, scheduled between March 29th and 31st in Chicago. The company said it would also showcase its new AI-powered innovation, including the CardIQ Suite, designed to improve efficiency and data integration across the cardiology care pathway. 'The future of healthcare lies in the integration of advanced technologies with human expertise, allowing for a more holistic, data-driven and efficient cardiology care pathway. Cardiovascular diseases are the leading cause of death globally, so it is critical that we continue our commitment to innovations in this space – our newest solutions showcased at ACC will help transform and optimize the diagnostic workflow.' Overall, GEHC ranks 5th on our list of top AI ratings and news updates on Wall Street's radar. While we acknowledge the potential of GEHC as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GEHC but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
05-03-2025
- Business
- Yahoo
GE HealthCare Technologies (NasdaqGS:GEHC) Unveils Genesis Cloud Solutions To Advance Digital Healthcare Transformation
GE HealthCare Technologies introduced Genesis Solutions, a new portfolio of cloud enterprise imaging SaaS solutions, aimed at enhancing efficiency and precision in healthcare. This development occurred amid a challenging market environment, with major indexes alternating between gains and losses, influenced by tariff discussions and mixed economic data. The company's share price moved 1.57% over the last quarter, a potentially modest increase considering the launch of Genesis, as well as recent upcoming products like Freelium and Flyrcado. Additionally, the company reported strong Q4 2024 earnings with increased revenue and net income, factors that likely held shareholder interest. Despite market volatility and broader economic concerns, GE HealthCare's innovations and market position kept investor confidence relatively stable compared to a broader market decline of 3.1% over the same period. Overall, the company's strategies and product developments may have offset broader market trends. Take a closer look at GE HealthCare Technologies's potential here. In the last year, GE HealthCare Technologies experienced a total return decline of 8.03%, underperforming both the US Medical Equipment industry, which saw a 9.7% gain, and the broader US market, which rose by 13.1%. While the company's earnings grew significantly by 43.5%, revenues only increased marginally at 3.8% annually, which may have deterred investors accounting for slower growth prospects compared to market expectations. The company's guidance for moderate organic revenue growth, between 1% to 2%, further tempered investor enthusiasm amid macroeconomic pressures such as weakness in the China market. Despite these challenges, GE HealthCare's product innovations, including the launch of the Freelium MRI platform, which uses less than 1% helium, and the Flyrcado PET MPI agent, highlight its commitment to advancing technological solutions. Additionally, the strategic partnership with UCSF to advance imaging solutions signals a strong focus on clinical improvement. Nonetheless, these developments were not enough to counterbalance the broader market headwinds impacting its share performance over the period. Understand the fair market value of GE HealthCare Technologies with insights from our valuation analysis—click here to learn more. Assess the potential risks impacting GE HealthCare Technologies' growth trajectory—explore our risk evaluation report. Already own GE HealthCare Technologies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:GEHC. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
